T he only treatment currently licensed for acute ischemic stroke is thrombolysis with intravenous recombinant tissue-type plasminogen activator (rtPA) originally approved for use within 3 hours of onset. A recent updated pooled analysis of 8 randomized controlled trials (RCTs) of rtPA treatment up to 6 hours after onset demonstrated efficacy up to 4.5 hours without a corresponding increase in hazard of intracerebral hemorrhage. 1 Even before this, results from the third European Cooperative Acute Stroke Study (ECASS III) 2 prompted expert groups in North America, Australia, Europe, and the United Kingdom to recommend rtPA treatment for eligible patients between 3 and 4.5 hours after onset. [3] [4] [5] Since then there has been a substantial increase in the number of patients treated beyond 3 hours in Europe. 6 Nonetheless, the benefit from rtPA remains critically dependent on the time to treatment with an exponential decay in the odds of a favorable outcome from one 90-minute interval to the next up to 4.5 hours. 7 This has led to concern that extension of the time window may result in treatment being delayed by the perception that more time remains in which to treat. 7, 8 This concern may be justified; several studies have reported that patients arriving earlier in the existing 3-hour time window are subject to delays in treatment, presumably resulting from less urgency when more time remains. 9 - 13 The latest large-scale US and European data sets confirm a strong correlation between time remaining to treat and time taken to treat with considerably shorter hospital arrival-to-treatment (ATT) times as the treatment deadline approaches. 6, 13 What is more, the United Kingdom has a median onset-to-treatment (OTT) time of approximately 155 minutes 14 compared with close to 90 minutes in the original RCT. 15 With over half of all patients being treated in the last 30 minutes before the treatment deadline or later, any loss of urgency would affect the majority of treated patients. If the extension of the time window and the loss of the 3-hour "deadline effect" were to delay treatment for most patients to even a relatively small extent such that they were treated at a lower absolute benefit, this may jeopardize the population benefit that should otherwise accrue from treating additional patients beyond 3 hours.
We therefore sought to quantify the population benefit of rtPA treatment from an extension to the time window from 3 to 4.5 hours in a model derived from UK patients registered in the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry (SITS-ISTR). 14,16
Methods
We constructed a Monte Carlo simulation in Microsoft Excel from prospective data from 3830 UK patients treated with rtPA registered in SITS-ISTR between January 2005 and February 2010. We excluded 191 patients from a small number of centers before 2005 because of large variability in the data in this period. In the model, a notional cohort of 1000 patients progresses along a pathway consisting of 3 phases: onset to hospital arrival (OTA), arrival to scan (ATS), and scan to treatment. A Monte Carlo simulation was used to sample from a representative probabilistic density function based on the respective population distribution of times for each phase of treatment. Further probabilistic sampling was then used to assign outcomes to each patient based on (1) whether or not they received rtPA; and (2) their individual OTT time. The model encompassed potential interactions between the different phases of treatment such as the effect of reductions in ATS and scan to treatment associated with later OTA times-the deadline effect. The model consisted of patients diagnosed with acute ischemic stroke and eligible for thrombolysis who arrived at hospital within 270 minutes of stroke onset (see online-only Data Supplement). Because our analysis was concerned only with the incremental outcomes between the 180-and 270-minute scenarios, patients with hemorrhagic stroke or other contraindications to thrombolysis were excluded because they had identical outcomes in both scenarios.
Data Sources
Data to populate the model were drawn from 3830 UK patients treated with rtPA in SITS-ISTR. We excluded 284 patients with an OTA time of zero (assumed to be strokes occurring in the hospital) and 59 patients with OTT times Ͼ300 minutes. We also excluded a further 319 patients treated 2 months either side of the publication of ECASS III in September 2008 2 to minimize contamination from anticipation of the study results and only included patients from centers with records in both periods to minimize bias from a learning effect (excluding 290 patients). From the remaining 2878 patients (1378 before August 1, 2008 , and 1500 after November 30, 2008), we derived population time distributions for the 3 phases of treatment (OTA, ATS, scan to treatment).
Outcome Measures
We described disability outcomes for the 2 periods before and after the publication of ECASS III using the modified Rankin Scale (mRS) at 90 days after treatment, dichotomized between an mRS of 0 to 1 (a favorable outcome indicating survival with minimal or no disability) and an mRS of 2 to 6 (an unfavorable outcome indicating survival with significant disability or death). 1, 15 We used the pooled analysis from Lees et al 1 to estimate the benefit from thrombolysis treatment. In the model, we used these probabilities to sample a mRS outcome for each simulated patient.
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Results
For 2878 patients, we identified the following median (interquartile range) times from onset to treatment: OTA: 75 (54) minutes, ATS: 31 (30) minutes, scan to treatment: 25 (26) minutes, ATT: 63 (42) minutes, and OTT: 150 (59) minutes. Figure 1 shows the distribution of OTT times before and after publication of ECASS III and shows a marked increase in the annual rate of treated patients in keeping with the steep growth elsewhere in Europe. 6 A greater proportion of patients were treated between 120 and 180 minutes in the pre-ECASS III data set with an increase in the number of patients treated Ͼ3 hours post-ECASS III. Table 1 shows the times for the main treatment phases before and after publication of ECASS III.
We examined the relationship between OTA time and reductions in the ATS and scan to treatment phases as the treatment deadline approaches (the deadline effect). To eliminate the effect of censoring at 3 hours, we limited the analyses to patients treated within 180 minutes of onset before (nϭ1187) and after (nϭ1104) the publication of ECASS III. Figure 2 shows the mean ATT time against OTA time for patients pre-and post-ECASS III and identifies 2 features. First, as observed in previous studies, ATT times for patients treated within 3 hours reduce as OTA times increase, although because of the censoring in the data, the extent to which the reduction is due to a deadline effect cannot be definitively established. Second, after ECASS III there is an acceleration of treatment of 8 minutes (95% CI, 5.5-10.5 minutes) for earlier patients with an OTA time between 10 and 90 minutes, that is, those for whom the deadline is not imminent, probably representing improved processes. However, when OTA time is beyond 90 minutes, that is, when pre-ECASS III deadlines were imminent but post-ECASS III deadlines were not imminent, the 8-minute improvement is not seen.
This loss of the improvement effect for post-ECASS III patients arriving after 90 minutes suggests a relaxation of treatment urgency associated with the deadline extension, which corresponds to an average reduction in ATT time of 20% (95% CI, 14.5%-25.5%) for this OTA range. This confirms a significant reduction in ATT times as OTA times increase even after adjustment for censoring in line with other studies describing a correlation between time remaining to treat and time taken to treat in unadjusted data. 6,9 -13
Modeled Disability Outcomes
Our simulation modeled the number of patients from a notional sample of 1000 who could be expected to benefit from thrombolysis before and after the time window extension. Dichotomized scores for 90-day mRS were derived to estimate disability outcomes in each scenario. Based on our observations from the SITS-ISTR data set, the model took account of patients whose treatment is delayed, even to a small extent, by shifting the treatment deadline. In a sensitivity analysis, we investigated the impact of varying the deadline effect, described by the percentage reduction in ATT time for patients arriving in the 90 minutes before the treatment deadline (either 180 or 270 minutes). Table 2 shows the outputs for a range of deadline effects either side of the observed 20% value. With no deadline effect, 40.5% more patients are treated after extension with no cost in terms of delays for those treated within 180 minutes. However, with the observed deadline effect of 20%, extension results in the treatment of an additional 244 patients at a mean OTT of approximately 219 minutes, but 212 patients have their treatment delayed by a mean of 7.8 minutes. Figure 3 shows the frequency distributions of OTT times pre-and postextension for 2 levels of deadline effect (20% [8 minutes] and 50% [23 minutes]). As the deadline effect increases, the shaded area before the 180-minute point increases, representing those patients treated later postextension (ie, the "cost" of extending the treatment window). The equivalent-sized shaded area beyond the 180-minute point shows when these delayed patients are treated postextension. The area beneath the pale line represents those additional patients who are treated postextension (ie, the benefit of extending the treatment window). Thus, as the deadline effect increases, the effective cost of extending the treatment deadline (the number of patients whose treatment is delayed) also increases.
Projected Outcomes
We used the simulation to derive the population disability benefit (projected number of patients achieving a favorable outcome, mRS 0 -1) pre-and postextension for different levels of deadline effect (Figure 4 ; bold lines). At the observed deadline effect of 20%, an additional 5 patients per 1000 achieve a favorable outcome postextension. At greater levels of deadline effect, the difference between the projected outcomes pre-and postextension narrows to a point beyond 45% (equivalent to a mean delay for patients arriving within 90 minutes of the treatment deadline of approximately 20 minutes) where no additional population benefit accrues from the extension of the treatment window.
By contrast, Figure 4 also illustrates (narrow lines) the impact of a general reduction in ATT times if the deadline effect applied for patients at all values of OTA time, that is, if all patients were treated with the same urgency as a patient arriving within 90 minutes of the treatment deadline. In both the pre-and postextension simulations and with a deadline effect of Ն20%, delivering treatment more rapidly in all patients (by at least 8 minutes across all OTA times) yields a greater population benefit than the extension of the time window. 
Discussion
Our study used data from a large prospective registry of stroke thrombolysis in the United Kingdom to build a simulation model of the impact of extension of the treatment window after the publication of ECASS III. [2] [3] [4] [5] Extending the window could be expected to result in treatment of a further 4.7% of people with stroke 17 but at a lower absolute benefit. 1 Our study is the first to take account of the effect on clinical behavior of shifting the 180-minute deadline for patients presenting during the latter part of the treatment window and the first to quantify how finely balanced the benefits and disbenefits may be. These consequences are not theoretical: data for Ͼ100 000 patients with acute ischemic stroke in the US Get with the Guidelines (GWTG) data set have shown a strong correlation between the time remaining to treat and the time taken to treat in unadjusted data. 13 After adjustment for the effect of censoring, we estimate that for patients arriving in the final 90 minutes before the deadline, ATT times are reduced by 20% compared with patients arriving earlier.
Furthermore, we believe that our adjusted estimate of this deadline effect is conservative. The GWTG data set identified that patients arriving at the hospital in the second and third hours after known stroke onset had an ATT time 30% lower than patients arriving in the first hour. 13 In the updated analysis of the European SITS registry, 6 patients arriving within 30 minutes of onset took an average of 61 minutes longer to be treated than those arriving in the last 30 minutes of the 3-hour time window. After the publication of ECASS III, mean ATT times for patients arriving in the last 30-minute period lengthened from 24 to 45 minutes. 6 Our sensitivity analysis suggests that if the loss of urgency is pronounced, then a point may be reached where the extension of the time window from 3 to 4.5 hours confers no additional population disability benefit. Although our estimate of 20% for the deadline effect is below this "tipping point" (see Figure 4 ), the unadjusted data from the updated European SITS-ISTR (which includes the UK data) suggest that this tipping point may be exceeded. It might be argued that improvements in the emergency response will counteract the effect of delays in treatment after extension of the time window. Indeed, our analysis indicates, for patients arriving early in the treatment window, a reduction in ATT times between 2005 and 2010 of 8 minutes, probably as participating centers gained experience as described elsewhere. 13 However, it remains that a relatively small proportion of patients arrive in this early period even as overall numbers treated have markedly increased, and no similar reduction in ATT time is seen for the majority of patients who arrive later in the treatment window. This observation is an example of the second gap of research translation 18 : a failure to deliver in clinical practice the benefits for individuals and healthcare systems that should result from the full implementation of the primary research. Whereas in the original RCT of treatment within 3 hours the median OTT time was, by design, close to 90 minutes, 15 the latest figure for median OTT time from the UK SITS-ISTR is 150 minutes, an hour later, representing a substantial reduction in the absolute benefit compared with that promised by Data show the mean average outputs from 1000 separate replications of the simulation (each replication simulating a population of 1000 patients).
ATT indicates arrival-to-treatment; OTT, onset-to-treatment. *In the simulation, treatment was not achieved within 270 min for between 32 and 44 patients. the primary research. 7 In the latest Swedish data, 19 all the growth in thrombolysis since the publication of ECASS III has come in the Ͼ3-hour category with the number of patients treated before 3 hours actually declining by 4.4% per year since that point. As the European SITS-ISTR database shows, it is the preponderance of patients close to the 3-hour time point that is most at risk of a delay in treatment after extension, possibly by as much as 21 minutes. 6 Importantly, we do not interpret our findings as supporting any case against extending the window for rtPA treatment up to 4.5 hours, and we consider the efficacy of rtPA to be proved for individual patients treated between 3 and 4.5 hours. 1 However, our study highlights the pitfalls of real-life implementation of research evidence, which cannot be successfully implemented without considering all the factors that may diminish the anticipated benefit. In so doing, our findings send out a significant warning to those involved with the emergency response for stroke. Patients arriving early in the time window should be treated with the same urgency as if time were imminently running out, and every patient should be treated as quickly as is compatible with safe practice. Healthcare systems need to ensure the delivery of thrombolysis at a median OTT time as close as possible to that seen in the original trial, 15 which may involve revising current guidance regarding timescales for assessment and treatment after hospital arrival. 20 If the same coordinated effort and resources were directed to this target as were directed to the conduct of the major commercial RCT of rtPA between 3 and 4.5 hours, 2 our study indicates that at least as much further population benefit could accrue.
We recognize the limitations of our study: the adjusted estimate of the deadline effect may be too conservative, although as shown in our sensitivity analysis, this would understate both the adverse impact of shifting the treatment deadline and the benefits of faster treatment. Our study has not modeled variation in OTA times, which has been the focus of a recent public education campaign in the United Kingdom. The latest UK audit suggests this campaign has not had a significant impact on OTA times with the proportion of people with stroke arriving at the hospital within 3 hours unchanged between 2008 and 2010. 21 However, in the United States, the GWTG data set showed a steady if small increase in the proportion of patients arriving within the first hour after onset. 13 Another limitation is the voluntary nature of the SITS registry, which may introduce reporting bias. There may be those who suggest there is no purpose in monitoring rtPA use now that the regulatory authorities in Europe have been reassured that the use of rtPA in clinical practice is, if anything, safer than in the original RCTs. 16 Our study indicates that continuous monitoring for unintended effects should be mandatory if the anticipated benefits from extension of the window are not to be jeopardized.
In summary, our simulation study of the effect of extension of the time window for the treatment of acute ischemic stroke has for the first time quantified the risk of treating larger numbers of patients but at a lower absolute benefit and the benefit from making comparatively modest but universally applied reductions in hospital delays. It sends a clear message to those delivering the emergency response to suspected stroke. Progress in shortening OTT times for all patients has not occurred as might have been expected, and renewed effort is needed to minimize delays at every stage from onset to treatment and in particular radical steps to eliminate inhospital delays in treatment combined with continued monitoring. These elements are essential if the population benefit from thrombolysis for acute ischemic stroke promised by the original RCTs is not to be unwittingly jeopardized but instead realized in clinical practice.
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Introduction
This on-line supplement provides technical details specific to the simulation model and analysis reported in the paper reference above.
Model Structure
In order to model the impact of treatment delays for stoke patients receiving rt-PA (i.e. thrombolysis), a Monte-Carlo simulation model was constructed using Microsoft Excel. The modelled pathway is shown in Figure S1 below. Since the focus of our study was to compare populations of stroke patients who are eligible for thrombolysis, it was not necessary to include contra-indications and ineligible patients in our model or to factor in patients arriving with an Onset to Arrival time (OTA) greater than 270 minutes since the pathway and outcome for these patients would not vary between the compared scenarios (and would hence be cancelled out in the incremental analysis). Within our model, therefore, the only reason for a patient not to receive rt-PA is when their Onset-to-Treatment time (OTT) exceeds the time threshold defined by the modelled scenario conditions. 
Data Sources and Methods
In our model the key time intervals for each patient were determined by sampling from a series of representative empirical distribution functions (edfs). These edfs are the observed distribution functions presented by the SITS-ISTR data as describe in the paper and summarised in Table S1 below. Differences between mean and median values in Table S1 demonstrate the positively skewed nature of these distributions. Table S1 . Summary of probability distributions used to model time delays before treatment
Data
The deadline effect was included in our model by applying a scale factor to sampled ATS and STT times corresponding to the level of deadline effect modelled in the sensitivity analyses. A deadline effect of x% was therefore modelled by scaling the sampled ATS and STT times for an individual patient by multiplying the sampled time value by (100-x)%. Application of the deadline effect within the model was dependant on how close the patient's current delay from onset time was to the defined treatment threshold time of the modelled scenario. The deadline effect was applied only for those patients whose current delay from onset was within 90 minutes of the treatment deadline and a stepped system was used whereby those patients whose current delay from onset was within an hour of the modelled treatment deadline experienced the full deadline effect whilst patients whose current delay from onset was between 60 and 90 minutes of the treatment deadline experienced half the overall deadline effect.
In order to model patient outcomes within the simulation, a modified Rankin Score (mRS) after 90 days was assigned to each modelled patient. This was determined by a probability function and affected by two key factors, firstly whether the patient had received rt-PA and secondly, for those patients who receive rt-PA, the OTT of the patient. The probabilistic relationship between these two factors and likelihood of an outcome mRS < 2 (after 90 days) is described in detail by the pooled analysis given in Lees et al 1 and shown below in Table S2 . Within our model, simulated patients were assigned to one of these three groups dependant on their OTT. The probability of achieving an MRS < 2 was then calculated for each patient group based on the Lees et al data.
These probabilities (shown in Table S2 ) were assumed to apply to the mid-point of the referenced OTT interval and linear interpolation was used, where an OTT of 270 minutes was assumed to have a probability of an mRS < 2 outcome equivalent to an untreated patient, to obtain a continuous probability function to represent the likelihood of patients attaining an mRS < 2 for all relevant values of OTT for each simulated patient in each of the separate groups.
OTT treatment period Table S2 . Relationship of time from onset to treatment and probability of a favourable (taken from Lees et al 1 )
Model Outputs
The simulation was primarily used to compare two scenarios 1) 'Pre-ECASS III' treatment where the OTT deadline for rt-PA treatment was 180 minutes and (2) 'Post-ECASS III' treatment where the rt-PA deadline was extended to patients with an OTT up to 270 minutes. The key sensitivity parameter of interest in this analysis was the level of 'deadline effect' as defined in our paper and these outputs are presented in the main text.
In each trial run of the model a notional population of 1000 patients were simulated for each arm of the simulation. The mean outputs from a total of 1000 replications of the model (each with a 1000 patient population) were recorded for each separate analysis to mitigate the effects of any within-sample variability.
The primary results from our simulation are presented in the main paper. We did however conduct a range of sensitivity analyses by varying individual input parameters in the model to explore the impact of changes. These outputs are presented in Table S3 below and for each analysis show:
 firstly, the additional patients treated in the post-ECASS III scenario versus the pre-ECASS III scenario which represents the effective benefit of increasing the treatment deadline.  secondly, the number of patients who experienced treatment delay (and the average delay accrued by these patients) due to the deadline effect within the extended deadline scenario which represents the effective cost to patient population of the post-ECASS III extension given the assumed deadline effect.
In order to vary the sampled distributions for OTA, ATS and STT in our model we used parameterised log-normal distributions.
These analyses demonstrate that the impact of the deadline effect level applies relatively consistently across a range of OTA, ATS and STT values. 
